AIM ImmunoTech Inc. (AIM)

0.4000 -0.0366 (-8.38%) 收市：03:59PM EDT

AIM ImmunoTech Inc.

2117 SW Highway 484
Ocala, FL 34473
United States
352 448 7797
https://aimimmuno.com

版塊: Healthcare
行業: Biotechnology
全職員工: 26

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Thomas K. Equels Esq., J.D., M.S.	Executive Vice Chairman, CEO & President	953.19k	無	1953
Mr. Robert Dickey IV, M.B.A.	Chief Financial Officer	64.48k	無	1956
Mr. Peter W. Rodino III, Esq., J.D.	COO, Executive Director of Governmental Relations, General Counsel & Secretary	484.94k	無	1951
Ann Marie E. Coverly	Director of Administration & Human Resources and Deputy Investor Relations Coordinator	無	無	無
Dr. Carol A. Smith	Chief Manufacturing Officer & Deputy Chief Scientific Officer	170.77k	無	1951
Dr. Christopher McAleer Ph.D.	Scientific Officer	無	無	無
Dr. Ralph Christopher Cavalli Ph.D.	Vice President of QC & Manufacturing	234.79k	無	1958

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

公司管治

截至 無 止，AIM ImmunoTech Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。